基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 PTC-209HBR 化合物 PTC-209 HBr
  • 化合物 PTC-209 HBr|T6178|TargetMol

化合物 PTC-209 HBr|T6178|TargetMol

PTC-209 hydrobromide
1217022-63-3
￥6960 100mg 起订
￥517 2mg 起订
￥849 5mg 起订
上海 更新日期：2024-12-12

TargetMol中国（陶术生物）

VIP3年
联系人：邵小姐
手机：4008200310 拨打
邮箱：marketing@tsbiochem.com

产品详情:

中文名称：
化合物 PTC-209 HBr
英文名称：
PTC-209 hydrobromide
CAS号：
1217022-63-3
品牌：
TargetMol
产地：
美国
保存条件：
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
产品类别：
抑制剂
货号：
T6178

Product Introduction

Bioactivity

NamePTC-209 hydrobromide
DescriptionPTC-209 hydrobromide (PTC-209 HBr) is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).
Cell ResearchTo determine whether pretreatment with the inhibitor affects tumor cell growth, cells are plated with the inhibitor for 4 d in vitro and plated in limiting doses in vitro without adding further inhibitor. Trypan blue exclusion is used to count viable cells. The in vitro sphere-initiating cell frequency is calculated after inhibitor treatment by evaluating the number of wells containing spheres. For the experiments where LDAs are set up following recovery of PTC-209 treated cells, 6-well plates were seeded with 1E6 cells per well and incubated overnight. Cells are subsequently treated for 4 d in triplicate with either DMSO vehicle or PTC-209 (0.01, 0.1, 1 and 10 μM). Drug treatments are washed off and 4 mL fresh suspension medium added to all wells. To assess cell viability following the 4 d treatment window, cells are trypsinized and counted at 0, 24, 72 and 120 h after removal of the drug. Long-lasting effects of the drug treatment on sphere-forming ability are assessed by plating LDAs (50,000, 10,000, 1,000,100, 10 and 1 cell per well) using the cells obtained 120 h after the 4-d drug treatment.(Only for Reference)
Kinase AssayUntranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control.
In vitroPTC-209在人类结直肠癌细胞HCT116和人类纤维肉瘤细胞HT1080中同时抑制UTR介导的报告基因表达和内源性BMI-1表达。PTC-209通过BMI-1依赖的方式减缓结直肠肿瘤细胞生长。此外，PTC-209还通过不可逆的生长抑制作用损害结直肠癌起始细胞(CICs)。[1]
In vivoPTC-209（60 mg/kg/天，皮下注射）有效抑制了肿瘤组织中BMI-1的产生，并在带有初级人类结肠癌异种移植物、人类结肠癌细胞系LIM1215或HCT116异种移植物的小鼠中停止了已建立肿瘤的生长。PTC-209还在体内减少了功能性结直肠CICs的频率。[1]
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationEthanol : <1 mg/mL
H2O : <1 mg/mL
DMSO : 93 mg/mL (161.4 mM)
Keywordscells | HEK293T | tumor | breast | cancer-initiating | Inhibitor | PTC-209 Hydrobromide | PTC209 | inhibit | colon | CICs | Autophagy | PTC 209 Hydrobromide | PTC 209 | PTC209 Hydrobromide | lung | PTC-209 | anti-myeloma | PTC209 hydrobromide | PTC 209 hydrobromide
Inhibitors RelatedOxyresveratrol | Guanidine hydrochloride | Naringin | Taurine | Gefitinib | Xylitol | Hydroxychloroquine | Curcumin | Stavudine | Myricetin | Paeonol | Sodium 4-phenylbutyrate
PTC-209 HBr|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 PTC-209 HBr相关厂家报价

  • PTC-209
  • PTC-209
  • 广州贝尔卡生物科技有限公司
  • 2024-03-04
  • 询价
内容声明
official 进入官方账号
拨打电话 立即询价